Daily PrEP reduces hip, spine BMD in HIV-seronegative patients

[...]changes in bone mineral density (BMD) at 24 weeks for patients taking Truvada (emtricitabine/tenofovir disoproxil fumarate, Gilead Sciences; FTC/TDF) was inversely correlated with intracellular tenofovir diphosphate (TFV-DP), which researchers identified in 53% of study patients.

Bibliographic Details

Published in:	Infectious Disease News 2015-09, Vol.28 (9), p.53
Main Author:	Craven, Jeff
Format:	Article
Language:	English
Subjects:	Bone density HIV Human immunodeficiency virus Osteoporosis Researchers
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!